Redhill Biopharma Ltd
RDHL
Company Profile
Business description
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Contact
21 Ha’arba’a Street
Tel Aviv6473921
ISRT: +972 35413131
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,642.20 | 20.90 | -0.24% |
| CAC 40 | 7,807.87 | 162.01 | -2.03% |
| DAX 40 | 22,839.56 | 662.69 | -2.82% |
| Dow JONES (US) | 46,021.43 | 203.72 | -0.44% |
| FTSE 100 | 10,063.50 | 241.79 | -2.35% |
| HKSE | 25,338.97 | 161.61 | -0.63% |
| NASDAQ | 22,090.69 | 61.73 | -0.28% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 12,946.03 | 105.58 | -0.81% |
| S&P 500 | 6,606.49 | 18.21 | -0.27% |
| S&P/ASX 200 | 8,448.80 | 23.50 | -0.28% |
| SSE Composite Index | 4,013.16 | 6.61 | 0.16% |